| Methods | D: parallel C: adequate B: double WD: 144/810 J: 2‐2‐1 DU: 4w/16w/‐ | |
| Participants | N: 810/783 (in intent‐to‐treat analysis, 808 in safety analysis) D: 72% migraine without aura C: IHS F: 81% A: 17‐66 years DU: 0.8 to 57 years S: 130 centres in 8 countries | |
| Interventions | P: 160 mg (slow‐release) C1: Flunarizine 10 mg C2: Flunarizine 5 mg | |
| Outcomes | R: 125/258 vs. 141/264 vs. 118/259 F: 1.7 (sd 1.6) vs. 1.6 (1.6) vs. 1.8 (1.2) AU: 0.9 vs. 1.1 vs. 1.1 migraine attacks treated symptomatically AEs: 88/270 vs. 88/275 vs. 88/263 Dropouts‐AEs: 18/270 vs. 19/275 vs. 21/263 V: 0 vs. C1, 0 vs. C2 | |
| Notes | Excellent, large, multicentre study Standard deviations for frequency calculated from reported 95% CIs | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Low risk | A ‐ Adequate |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.